Market Overview

Boston Scientific Launches Emerge PTCA Balloon Dilatation Catheter in the U.S.

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge™ Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary arteries. Both the Monorail® and Over-The-Wire (OTW) options are available. The Emerge Catheter has been commercially available in CE Mark countries since earlier this year.

"The Emerge Balloon Catheter combines Boston Scientific's innovative balloon technologies into a single platform," said J. Tift Mann, III, M.D., at Wake Heart & Vascular, Raleigh, North Carolina. "The result is exceptional deliverability and reliable performance in a wide range of anatomy and lesion types."

Posted-In: News FDA

 

Related Articles (BSX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional